Metabolomic profiling identified 14 blood metabolites that distinguished chronic from occasional cannabis users with 80% accuracy, and found distinct metabolic signatures during actual cognitive impairment versus non-impaired cannabis use.
Policymakers working on cannabis driving laws, forensic scientists, and researchers developing impairment tests.
14 metabolites distinguished chronic from occasional users with 80% accuracy, with unique impairment signatures
What the researchers found
Occasional and chronic cannabis users had distinctly different metabolic fingerprints at baseline (not intoxicated). 14 metabolites, mainly from endocannabinoid and amino acid metabolism, distinguished chronic from occasional users with 80% classification accuracy. During acute intoxication, only occasional users (who showed actual cognitive impairment) had distinct metabolomic changes including increases in organic acids, beta-hydroxybutyrate, and ceramides.
Why it matters
Current drug tests can only confirm cannabis use, not impairment. This study demonstrates that metabolomics could potentially identify the state of actual cognitive impairment, which would be far more useful for driving law enforcement and clinical assessment.
The numbers in context
35 participants (occasional and chronic users). 14 distinguishing metabolites identified. 80% classification rate (95% CI: 61-91%) for chronic vs occasional users. Distinct intoxication metabolites found only in occasional users who showed actual impairment.
How the study worked
Placebo-controlled study with 35 occasional and chronic cannabis users who received cannabis (300 microg/kg THC) and placebo. Blood samples collected at baseline and repeatedly over 70 minutes. Sustained attention and subjective high assessed. Metabolomic fingerprinting via mass spectrometry.
What this study cannot tell us
Small sample (35). Only one THC dose tested. 70-minute post-treatment window may not capture all metabolic changes. Metabolomics approach requires specialized equipment not available in field settings. Needs validation in larger, more diverse samples.
How to read the evidence
Moderate: controlled study with placebo comparison and objective cognitive measures, but small sample and early-stage metabolomics that needs validation.
When this study was published
2025 study.
The bigger picture
This represents a potential breakthrough in the cannabis impairment detection problem. If metabolomic markers can distinguish impairment from mere use, they could replace arbitrary blood THC thresholds with biologically meaningful impairment indicators.
Questions still open
- Could these metabolomic markers be developed into a practical roadside impairment test? Do different cannabis products produce different metabolomic signatures? Would these markers work across diverse populations?
Common questions
Could a blood test eventually detect cannabis impairment?
Why were chronic users different?
Read the original research
Metabolomic profiling of cannabis use and cannabis intoxication in humans.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 50(6), 920-927
Citation
Madrid-Gambin, Francisco; Haro, Noemí; Mason, Natasha L; Mallaroni, Pablo; Theunissen, Eef L; Toennes, Stefan W; Pozo, Oscar J; Ramaekers, Johannes G. (2025). Metabolomic profiling of cannabis use and cannabis intoxication in humans.. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 50(6), 920-927. https://doi.org/10.1038/s41386-025-02082-7